ReviewJournal of primary care & community health
Human Papillomavirus Vaccination Beyond Age 26: Evidence, Limitations, And Implications For Vaccination Policy.
Review in Journal of primary care & community health. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Human papillomavirus (HPV) is the most prevalent sexually transmitted infection globally and a major cause of anogenital and oropharyngeal cancers. Prophylactic HPV vaccination is most effective when administered before sexual debut and is routinely recommended for adolescents and young adults up to 26 years of age. However, ongoing HPV exposure throughout adulthood has prompted increasing interest in vaccination beyond this age group.This narrative review examines evidence for HPV vaccination in adults aged 26 years and older from randomized trials, observational studies, and modeling analyses, with a focus on immunogenicity, clinical effectiveness, safety, and population-level impact. Data from randomized controlled trials, immunogenicity-bridging studies, and modeling analyses indicate that HPV vaccines remain highly immunogenic and safe in mid-adult adults and can prevent new infections with vaccine-covered HPV types. Nevertheless, the overall public health benefit and cost-effectiveness of extending routine vaccination to this age group are limited, largely due to prior HPV exposure and indirect protection conferred by established adolescent vaccination programs.Overall, current evidence does not support routine HPV vaccination beyond age 26 at a population level. However, vaccination may still provide individual benefit in selected adults with ongoing or anticipated risk of new HPV exposure. These findings support a targeted, risk-based approach guided by shared clinical decision-making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.